Patents by Inventor Ramachandran Thirucote
Ramachandran Thirucote has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220265679Abstract: This invention relates to proliposomal powder dispersions of testosterone undecanoate (TU) and phospholipids, including dispersions of TU and palmitoylphosphatidylcholine (DPPC), wherein the weight/weight (w/w) ratio of TU:DPPC in the proliposomal powder dispersion is about 1:2; or TU and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), wherein the weight/weight (w/w) ratio of TU:DMPC in the proliposomal powder dispersion is about 1:3; or TU and a 1-myristoyl-2-palmitoyl-sn-glycero 3-phosphocholine (MPPC), wherein the weight/weight (w/w) ratio of TU:MPPC in the proliposomal powder dispersion is about 1:3.Type: ApplicationFiled: August 10, 2020Publication date: August 25, 2022Inventors: Veeran Gowda KADAJJI, Natarajan VENKATESAN, Nitin K. SWARNAKAR, Teresa HONG, Ramachandran THIRUCOTE, Guru V. BETAGERI
-
Patent number: 11389473Abstract: Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treatment of pain (such as migraine headache) comprising co-administration of an oxytocin peptide and a magnesium salt.Type: GrantFiled: January 7, 2016Date of Patent: July 19, 2022Assignee: Tonix Pharmaceuticals Holding Corp.Inventors: David C. Yeomans, Dean Carson, Ramachandran Thirucote
-
Patent number: 11229602Abstract: Compositions and methods for making and using proliposomal and liposomal formulations of chemotherapeutic agents are disclosed. The proliposomal and liposomal formulations of chemotherapeutics, as well as medicaments and dosage forms that include such formulations, can be used with treatment regimens for bladder cancer and urothelial cancer. Hence, the formulations, medicaments, and dosage forms of the invention are suitable to treat bladder cancers by intravesical administration and to treat urothelial cancers. The formulations according to the invention include (a) a taxane (e.g., paclitaxel, docetaxel) or cisplatin, (b) a first phospholipid, dipalmitoyl phosphatidylcholine (DMPC), and (c) a second phospholipid, dimyrsityl phosphatidyl glycerol sodium (DMPG). The proliposomal formulations form liposomes upon contact with an aqueous vehicle.Type: GrantFiled: January 9, 2017Date of Patent: January 25, 2022Assignees: WESTERN UNIVERSITY OF HEALTH SCIENCES, TESORX PHARMA, LLCInventors: Guru V. Betageri, Natarajan Venkatesan, Michael G. Oefelein, Ramachandran Thirucote, Nitin Kumar Swarnakar, Teresa Hong
-
Publication number: 20220000777Abstract: The invention described herein is directed to treating neoplasms by intraperitoneal administration of liposomal formulations of chemotherapeutic drugs. Methods of instilling liposomal formulations of taxane and platin chemotherapeutic agents into the peritoneal cavity of a subject to treat ovarian cancer or a primary peritoneal cancer are disclosed.Type: ApplicationFiled: November 4, 2019Publication date: January 6, 2022Inventors: Michael G. OEFELEIN, Natarajan VENKATESAN, Nitin K. SWARNAKAR, Teresa B. HONG, Guru V. BETAGERI, Ramachandran THIRUCOTE, Lining Zhu HUTCHINSON
-
Publication number: 20210267896Abstract: Compositions and methods for making and using proliposomal and liposomal formulations of chemotherapeutic agents are disclosed. The proliposomal and liposomal formulations of chemotherapeutics, as well as medicaments and dosage forms that include such formulations, can be used with treatment regimens for bladder cancer and urothelial cancer. Hence, the formulations, medicaments, and dosage forms of the invention are suitable to treat bladder cancers by intravesical administration and to treat urothelial cancers. The formulations according to the invention include (a) a taxane (e.g., paclitaxel, docetaxel) or cisplatin, (b) a first phospholipid, dipalmitoyl phosphatidylcholine (DMPC), and (c) a second phospholipid, dimyrsityl phosphatidyl glycerol sodium (DMPG). The proliposomal formulations form liposomes upon contact with an aqueous vehicle.Type: ApplicationFiled: May 19, 2021Publication date: September 2, 2021Applicants: WESTERN UNIVERSITY OF HEALTH SCIENCES, TESORX PHARMA, LLCInventors: Guru V. BETAGERI, Natarajan VENKATESAN, Michael G. OEFELEIN, Ramachandran THIRUCOTE, Nitin Kumar SWARNAKAR, Teresa HONG
-
Publication number: 20190248830Abstract: Novel testosterone undecanoate (TU) formulations are disclosed in which TU is incorporated into proliposomal powder dispersions of TU and distearoyl phosphatidylcholine (DSPC). The proliposomal powder dispersions of the invention can also be combined with pharmaceutically acceptable excipients, and incorporated into enterically coated oral dosage forms that are useful for testosterone replacement therapy.Type: ApplicationFiled: January 9, 2017Publication date: August 15, 2019Applicants: Western University of Health Sciences, Tesorx Pharma, LLCInventors: Guru V. BETAGERI, Ramachandran THIRUCOTE, Veeran Gowda KADAJI, Natarajan VENKATESAN
-
Publication number: 20180303850Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: ApplicationFiled: November 29, 2017Publication date: October 25, 2018Applicants: WESTERN UNIVERSITY OF HEALTH SCIENCES, TESORX PHARMA, LLCInventors: Guru V. BETAGERI, Ramachandran THIRUCOTE, Veeran Gowda KADAJJI
-
Publication number: 20170368095Abstract: Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treatment of pain (such as migraine headache) comprising co-administration of an oxytocin peptide and a magnesium salt.Type: ApplicationFiled: January 7, 2016Publication date: December 28, 2017Applicant: Trigemina, Inc.Inventors: David C. YEOMANS, Dean CARSON, Ramachandran THIRUCOTE
-
Patent number: 9844557Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: GrantFiled: September 19, 2016Date of Patent: December 19, 2017Assignees: WESTERN UNIVERSITY OF HEALTH SCIENCES, TESORX PHARMA, LLCInventors: Guru V. Betageri, Ramachandran Thirucote, Veeran Gowda Kadajji
-
Publication number: 20170173277Abstract: Disclosed herein are vials and devices containing a ketorolac solution for intranasal administration and a head space comprising no more than about 10% v/v oxygen and which vials and devices are stored in an oxygen-impermeable pouch. Also disclosed are processes for preparing the vials and devices.Type: ApplicationFiled: March 3, 2017Publication date: June 22, 2017Applicant: EGALET US, INC.Inventors: Roger Whiting, Ramachandran Thirucote
-
Patent number: 9629894Abstract: Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treatment of pain (such as migraine headache) comprising co-administration of an oxytocin peptide and a magnesium salt.Type: GrantFiled: January 7, 2016Date of Patent: April 25, 2017Assignee: TRIGEMINA, INC.Inventors: David C. Yeomans, Dean Carson, Ramachandran Thirucote
-
Patent number: 9623033Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: GrantFiled: August 29, 2016Date of Patent: April 18, 2017Assignees: WESTERN UNIVERSITY OF HEALTH SCIENCES, TESORX PHARMA, LLCInventors: Guru V. Betageri, Ramachandran Thirucote, Veeran Gowda Kadajji
-
Publication number: 20170065614Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: ApplicationFiled: September 19, 2016Publication date: March 9, 2017Applicants: WESTERN UNIVERSITY OF HEALTH SCIENCES, TESORX PHARMA, LLCInventors: Guru V. BETAGERI, Ramachandran THIRUCOTE, Veeran Gowda KADAJJI
-
Publication number: 20160375036Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: ApplicationFiled: August 29, 2016Publication date: December 29, 2016Applicants: WESTERN UNIVERSITY OF HEALTH SCIENCES, TESORX PHARMA, LLCInventors: Guru V. BETAGERI, Ramachandran THIRUCOTE, Veeran Gowda KADAJJI
-
Patent number: 9445995Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: GrantFiled: January 26, 2015Date of Patent: September 20, 2016Assignees: WESTERN UNIVERSITY OF HEALTH SCIENCES, TESORX PHARMA, LLCInventors: Guru V. Betageri, Ramachandran Thirucote, Veeran Gowda Kadajji
-
Publication number: 20160193282Abstract: Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treatment of pain (such as migraine headache) comprising co-administration of an oxytocin peptide and a magnesium salt.Type: ApplicationFiled: January 7, 2016Publication date: July 7, 2016Inventors: David C. YEOMANS, Dean CARSON, Ramachandran THIRUCOTE
-
Publication number: 20160136089Abstract: This invention relates to therapeutic compositions, particularly sprayable aqueous compositions, and unit dose formulations comprise ketorolac or a pharmaceutically acceptable salt, alone or in combination with lidocaine or a pharmaceutically acceptable salt thereof. The compositions are nasally administered to a subject in need thereof to treat pain or inflammation.Type: ApplicationFiled: November 20, 2015Publication date: May 19, 2016Applicant: EGALET US, INC.Inventors: Roger Whiting, Ramachandran Thirucote
-
Publication number: 20150314084Abstract: Disclosed herein are devices and processes for preparing a vial for an intranasal administration of a medicament where the vial comprises reduced oxygen content.Type: ApplicationFiled: January 6, 2015Publication date: November 5, 2015Inventors: Roger Whiting, Ramachandran Thirucote
-
Publication number: 20150157572Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: ApplicationFiled: January 26, 2015Publication date: June 11, 2015Inventors: Guru V. Betageri, Ramachandran Thirucote, Veeran Gowda Kadajji
-
Patent number: 8957053Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: GrantFiled: January 7, 2014Date of Patent: February 17, 2015Assignees: Tesorx Pharma, LLC, Western University Health SciencesInventors: Guru V. Betageri, Ramachandran Thirucote, Veeran Gowda Kadajji